(MedPage Today) — SEATTLE — Risk of death was lower in the years after a bisphosphonate was started following a fracture rather than denosumab (Prolia), a target trial emulation found.
In adults ages 50 and older who experienced low-trauma…
Source link : https://www.medpagetoday.com/meetingcoverage/asbmr/117344
Author :
Publish date : 2025-09-06 20:30:00
Copyright for syndicated content belongs to the linked Source.
